Advertisement

Advertisement

Most Viewed Videos
Metastatic Urothelial Cancer: A Conversation on State-of-the-Art Treatment Before the ASCO20 Virtual Scientific Program
Barbara DeVivo, PhD, MBA, on Tumor Boards: The Influence of Social Hierarchy on Cancer Treatment Decision-Making
Steven J. O’Day, MD, on Triple-Negative Breast Cancer: Clinical Benefit With Pembrolizumab Plus Imprime PGG
Hope S. Rugo, MD, on Talazoparib for Advanced Solid Tumors: Reduced Hospitalization and Supportive Care
Qi Liu, PhD, on NSCLC: Pneumonitis, Immunotherapy, and Chemotherapy
Andrew X. Zhu, MD, PhD, on Hepatocellular Carcinoma: Atezolizumab Combined With Bevacizumab
Nancy E. Davidson, MD, on COVID-19 and Cancer Care: Thoughts From the Seattle Epicenter
Francesca Battaglin, MD, on Colorectal Cancer: Using Genetic Variants to Predict Treatment Efficacy
Rowan T. Chlebowski, MD, PhD, on Diet and Breast Cancer: Trial Results
Laura C. Michaelis, MD: In My Experience Question 2
Mehdi Hamadani, MD: In My Experience Question 2
William J. Gradishar, MD, on HR-Positive, HER2-Negative Advanced Breast Cancer: NCCN Guidelines Updates
Jeffrey A. Meyerhardt, MD, MPH, on Colon Cancer: Results From the ACTS-CC 02 Trial on Adjuvant Chemotherapy
Susan Blumel, RN, BSN, and Laura J. Zitella, MS, RN, ACNP-BC, AOCN, on Managing Toxicities of Immunotherapy
Jennifer K. Litton, MD, on Breast Cancer: EMBRACA Trial on Talazoparib vs Chemotherapy
Mikkael A. Sekeres, MD, on Cancer Treatment in the Age of COVID-19: Personal Observations
Jedd D. Wolchok, MD, PhD, on The Future of Immunotherapy: Keynote Lecture
Sara A. Hurvitz, MD, on Talazoparib vs Chemotherapy for Breast Cancer: Results From the EMBRACA Trial
Karen Wonders, PhD, on Benefits of Exercise During Cancer Treatment
Mehdi Hamadani, MD: In My Experience Question 6

Advertisement

Advertisement



Advertisement